BioDelivery Sciences International (NSDQ:BDSI) said today that the FDA approved a supplemental new drug application for its Bunavail buprenorphine and naloxone buccal film. The revised indication allows patients to use the product to initiate buprenorphine treatment for opioid dependence.
Induction is the initial process by which a patient transitions from abusing an opioid to buprenorphine treatment which is designed to relieve cravings and withdrawal, according to BioDelivery Sciences.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA OKs BioDelivery Sciences’ Bunavail opioid dependence film appeared first on MassDevice.